Update on Dupilumab: HSE Drugs Group Supports Reimbursement
Potentially life-changing treatment one step closer for people struggling with moderate-to-severe atopic eczema The HSE has advised that the HSE Drugs Group, the body which decides whether or not the Irish government will fund a new medicine through the public health system, supported reimbursement of dupilumab for a defined subgroup of the full licensed indication, […]
